semaglutide grey Medicare beneficiaries face higher costs, near-universal prior authorization for GLP-1 drugs Semaglutide for Weight Loss: Transform

Retatrutide is an investigational triple receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously

Hu X, Liu S, Liu X, Zhang J, Liang Y, Li Y

Visible brightening and reduced pigmentation typically appear after 48 weeks of consistent use with sunscreen

Eli Lilly responded to its rivals accusations with a statement saying that the trial which underpins its advertising, known as Surmount-5, is the only direct, head-to-head randomised clinical trial comparing tirzepatide and semaglutide in the context of weight management